Therapeutix

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic serious adverse events in the trial…

BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular…

BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular…

<!-- Name:DistributionId Value:8747335 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year…